Australia markets closed
  • ALL ORDS

    7,252.30
    +2.00 (+0.03%)
     
  • ASX 200

    6,995.20
    -3.60 (-0.05%)
     
  • AUD/USD

    0.7625
    -0.0029 (-0.37%)
     
  • OIL

    59.34
    -0.26 (-0.44%)
     
  • GOLD

    1,744.10
    -14.10 (-0.80%)
     
  • BTC-AUD

    78,372.87
    -2,009.12 (-2.50%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • AUD/EUR

    0.6401
    -0.0018 (-0.29%)
     
  • AUD/NZD

    1.0828
    -0.0010 (-0.10%)
     
  • NZX 50

    12,574.35
    -58.25 (-0.46%)
     
  • NASDAQ

    13,845.05
    +86.55 (+0.63%)
     
  • FTSE

    6,915.75
    -26.47 (-0.38%)
     
  • Dow Jones

    33,800.60
    +297.03 (+0.89%)
     
  • DAX

    15,234.16
    +31.48 (+0.21%)
     
  • Hang Seng

    28,698.80
    -309.27 (-1.07%)
     
  • NIKKEI 225

    29,768.06
    +59.08 (+0.20%)
     

Aroa Biosurgery Limited (ASX:ARX) Shares Could Be 27% Below Their Intrinsic Value Estimate

Simply Wall St
·4-min read

How far off is Aroa Biosurgery Limited (ASX:ARX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

See our latest analysis for Aroa Biosurgery

What's the estimated valuation?

We have to calculate the value of Aroa Biosurgery slightly differently to other stocks because it is a biotechs company. Instead of using free cash flows, which are hard to estimate and often not reported by analysts in this industry, dividends per share (DPS) payments are used. Unless a company pays out the majority of its FCF as a dividend, this method will typically underestimate the value of the stock. We use the Gordon Growth Model, which assumes dividend will grow into perpetuity at a rate that can be sustained. The dividend is expected to grow at an annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.0%. We then discount this figure to today's value at a cost of equity of 7.9%. Compared to the current share price of AU$1.1, the company appears a touch undervalued at a 27% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

Value Per Share = Expected Dividend Per Share / (Discount Rate - Perpetual Growth Rate)

= NZ$0.1 / (7.9% – 2.0%)

= AU$1.5

dcf
dcf

The assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Aroa Biosurgery as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.9%, which is based on a levered beta of 1.135. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Moving On:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Why is the intrinsic value higher than the current share price? For Aroa Biosurgery, we've compiled three fundamental factors you should explore:

  1. Risks: Every company has them, and we've spotted 2 warning signs for Aroa Biosurgery you should know about.

  2. Future Earnings: How does ARX's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every Australian stock every day, so if you want to find the intrinsic value of any other stock just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.